Výsledky vyhledávání - "T, Grüneisen"

Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG

Autor: T. Büchner, Wolfgang Kern, T. Grüneisen, Wolfgang Hiddemann, Bernhard Wörmann, A. Matylis, Christoph Huber, W. D. Ludwig, J. Ohnesorge, A. Grote-Metke

Publikováno v: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ISBN: 9783642621093

Fludarabine was shown to increase the intracellular formation of AraCTP during treatment with AraC both in vitro and in vivo and had significant activity in patients with advanced acute myeloid leukemia (AML) when used in combination with AraC in pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d844778c6156103e6ddd78e5eb7f13d2
https://doi.org/10.1007/978-3-642-18156-6_35

Zobrazit plný text záznamu

Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia

Autor: A. Matylis, T. Büchner, Bernhard Wörmann, J. Ohnesorge, W.-D. Ludwig, A. Grote-Metke, T. Grüneisen, W. Kern, Christoph Huber, W. Hiddemann

Publikováno v: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ISBN: 9783642621093

In order to assess the value of the addition of fludarabine as a chemo-modulator to a high-dose AraC based salvage regimen for patients with refractory and relapsed acute myeloid leukemia the German AML Cooperative Group initiated a prospective rando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8efed683977a3710ba37c0a0e551375
https://doi.org/10.1007/978-3-642-18156-6_92

Zobrazit plný text záznamu

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison

Autor: Cristina Sauerland, B. Lathan, Th. Büchner, A. Reichle, K. Becker, L. Balleisen, W. D. Ludwig, A. Bartholomäus, Wolfgang Hiddemann, R. Donhuijsen-Ant, T. Grüneisen, C. Aul, H. Köppler, Achim Heinecke, P. Bettelheim, G. Maschmeyer, R. Schönrock-nabuls

Publikováno v: Leukemialymphoma.

193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate dose cytosine arabinoside (AraC) both combined with mitoxantrone (mitox) according to the pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e1517ecc17c6245d6a2fd864c9a33b3
https://pubmed.ncbi.nlm.nih.gov/8481662

Zobrazit plný text záznamu

High-Dose Versus Intermediate-Dose Cytosine Arabinoside Combined with Mitoxantrone for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia: Results of an Age-Adjusted Randomized Comparison

Autor: T. Grüneisen, W. D. Ludwig, Th. Büchner, Leopold Balleisen, K. Becker, P. Bettelheim, Georg Maschmeyer, A. Reichle, Cristina Sauerland, H. Köppler, Wolfgang Hiddemann, R. Donhuijsen-Ant, R. Schönrock-Nabulsi, A. Bartholomäus, Achim Heinecke, C. Aul, B. Lathan

Publikováno v: Acute Leukemias ISBN: 9783540539490

In the treatment of relapsed and refractory acute myeloid leukemia (AML), cytosine arabinoside (AraC) is unanimously considered a highly active single agent when given in repeated doses of more than 500 mg/m2 up to 3000 mg/m2. Major dispute continues

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::291e8907eb360989ae2b9f5a41aef267
https://doi.org/10.1007/978-3-642-76591-9_67

Zobrazit plný text záznamu

Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM)

Autor: W, Hiddemann, H C, Aul, G, Maschmeyer, D, Urbanitz, B, Lathan, A, Reichle, H, Köppler, R, Donhuijsen-Ant, W D, Ludwig, T, Grüneisen

Publikováno v: Haematology and blood transfusion. 33

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1307e4f67169b479bf8c6eede6f45c4c
https://pubmed.ncbi.nlm.nih.gov/2182450

Zobrazit plný text záznamu

Proposal for the Classification of Relapsed and Refractory Acute Myeloid Leukemias as the Basis for an Age-Adjusted Randomized Comparison of Sequentially Applied High-Dose Versus Intermediate-Dose Cytosine Arabinoside in Combination with Mitoxantrone (S-HAM)

Autor: Th. Büchner, A. Reichle, Achim Heinecke, W. Schroyens, Georg Maschmeyer, P. Bettelheim, D. Urbanitz, Wolfgang Hiddemann, R. Donhuijsen-Ant, Hubert Köppler, W.-D. Ludwig, Leopold Balleisen, T. Grüneisen, B. Lathan, H. Bartels, C. Sauerland, H. C. Aul

Publikováno v: Acute Leukemias II ISBN: 9783540509844

In spite of the substantial improvement of first-line treatment in adult patients with acute myeloid leukemia (AML) and a grad-ual increase in long-term remissions, the majority of patients still relapse with their disease and ultimately die due to d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d4ee52ea8f95cfa6ddbe066b63c70b3
https://doi.org/10.1007/978-3-642-74643-7_110

Zobrazit plný text záznamu

Autor: Georg Maschmeyer, R. Donhuijsen-Ant, Wolfgang Hiddemann, D. Urbanitz, T. Grüneisen, R. Reichel, B. Lathan, Carlo Aul, H. Bartels, R. Hoffmann, T. Büchner, Peter Bettelheim, W.-D. Ludwig, Leopold Balleisen, Hubert Köppler

Publikováno v: Oncology Research and Treatment. 12:4-6

In a prospective randomized trial, the pending question was addressed whether Cytosine arabinoside (Ara-C) should be applied at high or intermediate dose to patients with relapsed or refractory acute myeloid leukemia. Based upon the previously establ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c3ea329c1f91d1b377c1d2298e547b6
https://doi.org/10.1159/000216586

Zobrazit plný text záznamu

Hinweise für Autoren – Instructions to Authors

Autor: C. Zielinski, M.E. Heim, A. Cortelezzi, C. Richter, W. Wilmanns, E. Lengfelder, P. Bettelheim, R. Donhuijsen-Ant, J. Drach, L. Nowicki, R. Hoffmann, H. Dietzfelbinger, A. Kriegisch, T. Wagner, E. Thiel, C. Gattringer, G. Schulz, I. Kuehrer, H. Illinger, C. v. Schilling, R. Voigtmann, A.C. Feller, H.-M. Reinold, R. Pirker, E. Fritz, B. Steinke, R. Reichel, H. König, H. Ludwig, G. Brittinger, W. Enne, K. Bross, K. Kabelitz, G. Michlmayr, T. Grüneisen, A. Ganser, R. Heinz, E. Schumacher, M.G. Willems, B. Lathan, K.R. Trott, T.G. Wendt, H. Gerhartz, B. Doerken, R. Kuse, M. Schaefers, I. Hofmann, D. Huhn, L. Balleisen, P. Preis, J. Thaler, H.H. Gerhartz, J. Heise, E.R. Kastenbauer, D. Metzner, L. Baldini, M. Engelhard, T. Büchner, E. Polli, E. Heidemann, M. Micksche, H. Löffler, R. Fuchs, B. Löffler, H. Radtke, W. Linkesch, A. Kraft, R. Keilhauer, K. Josten, D. Urbanitz, R.C. Hartenstein, A. Stacher, K. Lennert, W. Dornoff, H. Seibt, B. Schnabel, J.H. Karstens, J. Ammon, H. Stein, P. Meusers, W. Hettchen, W.D. Ludwig, H. Sommerkamp, G. Maschmeyer, T. Zwingers, C. Aul, D. Hoelzer, H. Huber, W. Siegert, K.H. Zurborn, H.J. Staiger, W. Scheithauer, H. Müller-Hermelink, H. Köppler, W. Hiddemann, D. Moldrzyk, H. Bartels, J. Düllmann, O.G. Ottmann, A. Greiner

Publikováno v: Oncology Research and Treatment. 11:272-272

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cf9e1da26fe2014a28fee86ef5c33d9
https://doi.org/10.1159/000216555

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání